Compositions and Methods for Inhibition of Pathogenic Bacterial Growth

Patent metadata

Field	Value
Publication number	US-2016243172-A1
Application number	US-201414765814-A
Country	US
Kind code	A1
Filing date	Feb 4, 2014
Priority date	Feb 4, 2013
Publication date	Aug 25, 2016
Grant date	—

Abstract

Compositions for methods of preventing or reducing pathogenic bacterial growth, proliferation, and/or colonization are described containing one or more types of non-pathogenic bacteria to be introduced into the gastrointestinal tract and effectively compete with pathogenic bacteria for monomeric or polymeric carbohydrate nutrients, and/or amino acid nutrients, and/or vitamin nutrients.

First claim

1 . A composition comprising an effective amount of a first type of bacteria and a second type of bacteria formulated for oral administration to a mammalian subject, wherein the first and second type of bacteria are: (i) isolated, (ii) not identical, and (iii) independently capable of proliferating in a nutrient medium having a threshold concentration of a nutrient below that concentration required for Clostridium difficile proliferation.

2 . The composition of claim 1 , wherein the nutrient comprises a carbohydrate nutrient.

3 . The composition of claim 2 , wherein the carbohydrate nutrient is selected from the group consisting of glucose, mannitol, fructose, N-acetylglucosamine (NAG) and N-acetylneuraminic acid (NAN).

4 . The composition of claim 1 , wherein the first and second type of bacteria are independently capable of proliferating in a nutrient medium having a threshold concentration of glucose, mannitol, fry close, N-acetylglucosamine (NAG) and N-acetylneuramic acid (NAN) below that concentration required for Clostridium difficile proliferation.

5 . The composition of claim 1 , wherein the threshold concentration is about 90% or less the concentration required for Clostridium difficile proliferation.

6 . The composition of claim 1 , wherein the threshold concentration is about 50% or less the concentration required for Clostridium difficile proliferation.

7 . The composition of claim 1 , wherein the threshold concentration is about 10%, about 5%, or about 1% the concentration required for Clostridium difficile proliferation.

8 . The composition of claim 1 , wherein the first and second type of bacteria are independently capable of proliferating at a rate at least 10% greater than Clostridium difficile in a nutrient medium having a concentration of a nutrient selected from the group consisting of glucose, mannitol, fructose, N-acetylglucosamine (NAG) and N-acetylneuraminic acid (NAN).

9 . The composition of claim 1 , wherein the first and second type of bacteria are independently capable of proliferating at a rate at least 50% greater than Clostridium difficile in a nutrient medium having a concentration of a nutrient selected from the group consisting of glucose, mannitol, fructose, N-acetylglucosamine (NAG) and N-acetylneuraminic acid (NAN).

10 . The composition of claim 1 , wherein the nutrient comprises a vitamin nutrient.

11 . The composition of claim 10 , wherein the vitamin nutrient is selected from the group consisting of biotin, pantothenate and pyridoxine.

12 . The composition of claim 11 , wherein the first and second type of bacteria are independently capable of proliferating in a nutrient medium having a threshold concentration of biotin, pantothenate and pyridoxine below that concentration required for Clostridium difficile proliferation.

13 . The composition of claim 11 , wherein the threshold concentration is about 90% or less the concentration required for Clostridium difficile proliferation.

14 . The composition of claim 11 , wherein the threshold concentration is about 50% or less the concentration required for Clostridium difficile proliferation.

15 . The composition of claim 11 , wherein the threshold concentration is about 10% or less the concentration required for Clostridium difficile proliferation.

16 . The composition of claim 1 , wherein the first and second type of bacteria are independently capable of proliferating at a rate at least 10% greater than Clostridium difficile in a nutrient medium having a concentration of a nutrient selected from the group consisting of biotin, pantothenate and pyridoxine.

17 . The composition of claim 1 , wherein the first and second type of bacteria are independently capable of proliferating at a rate at least 50% greater than Clostridium difficile in a nutrient medium having a concentration of a nutrient selected from the group consisting of biotin, pantothenate and pyridoxine.

18 . The composition of claim 1 , wherein the first and second type of bacteria are independently capable of proliferating at a rate at least 10% greater than Clostridium difficile in a nutrient medium having a concentration of biotin, pantothenate, pyridoxine, glucose, mannitol, fructose, N-acetylglucosamine (NAG) and N-acetylneuramic acid (NAN).

19 . A composition comprising an effective amount of a first type of bacteria and a second type of bacteria that are independently capable of proliferating at a rate at least 10% greater than Clostridium difficile in a nutrient medium having a limiting concentration of one or more essential carbohydrate nutrients.

20 .- 25 . (canceled)

26 . A method for the treatment of Clostridium difficile infection in a mammalian subject, comprising the step of orally administering to the subject a composition comprising an effective amount of a first type of bacteria and a second type of bacteria formulated for oral administration to a mammalian subject, wherein the first type of bacteria is: (i) isolated, (ii) not identical to the second type of bacteria, and (iii) independently capable of saccharification at a rate at least 10% greater than Clostridium difficile , and wherein the second type of bacteria is: (i) isolated, (ii) not identical to the first type of bacteria, and (iii) independently capable of glycolysis of a nutrient selected from the group consisting of glucose, mannitol, fructose, N-acetylglucosamine (NAG) and N-acetylneuramic acid (NAN), at a rate at least 10% greater than Clostridium difficile or at a concentration at least 10% less than Clostridium difficile , or the combination thereof, under conditions such that the first type of bacteria and the second type of bacteria functionally populate the gastrointestinal tract of the subject and prevent the population of the gastrointestinal tract by Clostridium difficile.

27 .- 46 . (canceled)

Assignees

• Seres Therapeutics Inc

Inventors

• Cook David N
• Zhang Han
• D'Onofrio Anthony Mario
• Berry David Arthur
• Mckenzie Mary-Jane Lombardo
• Aunins John Grant
• Mckenzie Gregory
• Ohsumi Toshiro K

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• A61P1/12

  Antidiarrhoeals · CPC title

• A61P1/04

  for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title

• A61K9/48

  Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)} · CPC title